Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer

Status Not yet recruiting

Clinical Trial Summary

This is a prospective study on the prevention of Neratinib-related diarrhea in a Chinese population, exploring the best options for reducing the incidence of neratinib-related diarrhea through either pharmacologic intervention (prophylactic antidiarrheal therapy) or non-pharmacologic intervention (dose escalation program).

Clinical Trial Description

This is A prospective, randomized, single-center clinical trial, divided into 3 groups (experimental group: group A and group B, control group: group C), planned sixty patients were enrolled, with 20 patients in each group. Experimental group: Group A (n=20) and group B (n=20) were given neratinib dose escalation regimen foranti-HER2 adjuvant therapy.In group A, the dose of neratinib climbed up to 240mg within 2 weeks, and in group B, the dose climbed up to 240mg within 4 weeks. Control group: Group C (n=20) was given 240mg neratinib initially, but prophylactic loperamide antidiarrhea treatment was given at the same time within 2 months. Diarrhea caused by neratinib often occurred within 1-2 months of initial treatment, so small dose of neratinib was used in both group A and group B at the time of initial treatment. The incidence and severity of neratinib-related diarrhea in the three groups were observed, and DFS and other neratinib-related adverse events were followed up for a long time. The study is to evaluate the safety and efficacy of neratinib dose escalation regimen and conventional dose combined with loperamide regimen in enhanced anti-HER2 adjuvant therapy for early HER2-positive breast cancer. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05154396
Study type	Interventional
Source	Chinese Academy of Medical Sciences
Contact	Peng Yuan
Phone	01087787245
Email	yuanpengyp01@163.com
Status	Not yet recruiting
Phase	Phase 2
Start date	January 1, 2022
Completion date	December 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04095390` - A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer	Phase 2
Recruiting	`NCT04578106` - Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy	Phase 2
Terminated	`NCT01912963` - Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer	Phase 2
Completed	`NCT01855828` - Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer	Phase 2
Terminated	`NCT01705340` - Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery	Phase 1
Recruiting	`NCT04094896` - TCHP Versus EC -THP as Neoadjuvant Treatment for HER2-Positive Breast Cancer	Phase 2
Recruiting	`NCT06087120` - Investigate the Prognostic and Predictive Value of ctDNA During Neoadjuvant Chemotherapy for Breast Cancer.
Recruiting	`NCT05346861` - Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab	Phase 3
Recruiting	`NCT04899908` - Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases	Phase 2
Completed	`NCT03330561` - PRS-343 in HER2-Positive Solid Tumors	Phase 1
Recruiting	`NCT04997798` - Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Cancer	Phase 2
Not yet recruiting	`NCT04034823` - KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer	Phase 2
Completed	`NCT04756921` - 18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response
Completed	`NCT03140553` - TCH Versus EC-TH as Neoadjuvant Treatment for HER2-Positive Breast Cancer	Phase 2
Completed	`NCT03094052` - Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib	Phase 2
Recruiting	`NCT05511844` - Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors	Phase 1
Recruiting	`NCT05325632` - Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab	Phase 2
Recruiting	`NCT06161922` - Real World Patient-Reported Outcomes in Chinese Her2+ EBC Patients Receiving (Neo) Adjuvant Anti-Her2 Based Therapy
Recruiting	`NCT05710666` - Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study)	Phase 2
Not yet recruiting	`NCT05063643` - Cardiotoxicity of Targeted Therapy for HER-2 Positive Breast Cancer Patients at High Altitude